| Document |
Document Title |
|
WO/1990/004396A1 |
Compounds of formula (I), wherein n is 1 or 2, R1 represents a hydrogen atom or a C1-C4 alkyl group, R2 represents a hydrogen atom and R3 represents a hydrogen atom or a hydroxy group or R2 and R3 together represent a chemical bond, R4 r...
|
|
WO/1989/008109A1 |
Substituted ergolines of general formula (I), and their acid addition salts, in which (a) and (b) denote a C-C single bond or a C=C double bond, X denotes oxygen or sulphur, R1 denotes amino, nitro or the (c) residue, R2 denotes methylth...
|
|
WO/1985/003878A1 |
Pharmaceutical composition for the transdermal systemic administration of an active agent characterised in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the tran...
|
|
WO/1983/003758A1 |
The composition is based on alkaloids of the ergot as lisurid with an affinity to monoamine receivers.
|
|
WO/1982/002892A1 |
The compounds have the formula I (FORMULA) wherein R1 is H, a C1-4 alkyl or their precursors, R2 is a C1-4 alkyl, R3 and R4 independently of each other are H, a C alkyl or together are a C alkylene, R5 is H or alkyl and A and B are each ...
|
|
WO/1982/000463A1 |
Compounds having the following formula I, (FORMULA) wherein R1 represents a straight alkyl group with 2 or 3 carbon atoms, R2 represents hydrogen or an alkyl group with 1 to 3 carbon atoms, R3 represents an alkyl group with 1 to 3 carbon...
|
|
JP6856532B2 |
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...
|
|
JP5955561B2 |
This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly ...
|
|
JP2016503795A |
The novel methysergide derivatives and compositions thereof are provided herein. In other embodiments, methods of treating, preventing, or ameliorating various medical disorders or symptoms thereof, such as migraine and Parkinson's disea...
|
|
JP2015525239A |
The present invention provides novel cabergoline analogs and compositions thereof. In other embodiments, the present invention provides methods of treating, preventing or ameliorating various medical disorders, such as migraine and Parki...
|
|
JP5351078B2 |
Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
|
|
JP5121703B2 |
Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1...
|
|
JP2012513446A |
The present invention relates to a novel use of 5-HT2A and 5-HT2B receptor antagonists for therapeutic or prophylactic treatment of patients with stenosis of the spinal canal and of the symptoms thereby caused in these patients.
|
|
JP4712975B2 |
Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
|
|
JP4637359B2 |
The invention concerns the use of nicergoline for preventing and/or treating motor neuron diseases.
|
|
JP4637360B2 |
The invention concerns the use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline for preventing and/or treating motor neuron diseases.
|
|
JP4593789B2 |
Process for the preparation of compounds active in the treatment of Parkinson's disease, and such compounds, having general formula (VI) wherein R4 may be, independently, a linear, branched or cyclic, saturated or unsaturated C1-8 alkyl ...
|
|
JP4570827B2 |
The invention concerns a novel method for preparing lysergic acid by isomerization of paspalic acid using a tetraalkylammonium hydroxide.
|
|
JP2009526030A |
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.
|
|
JP2009502895A |
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides...
|
|
JP4184666B2 |
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crys...
|
|
JP4181203B2 |
Disclosed is a series of dopamine analogs and pharmaceutical compositions comprising the same.
|
|
JP2007535526A |
The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing ca...
|
|
JP3996897B2 |
Disclosed is a series of dopamine analogs and pharmaceutical compositions comprising the same.
|
|
JP2007269809A |
To provide a new tropan analog that binds to a monoamine transporter. The tropan analog has the formula (wherein, R1is COR3, and α or β; R2is OH or O, and 6- or 7-substituent, with the proviso that when R2is OH, it is α or β; X is NR...
|
|
JP2007254470A |
To provide a pharmaceutical for preventing and treating a chronic pain state. Terguride and proterguride are used for preventing and treating the chronic pain state. The pharmaceutical composition is effective for a wide range of the pai...
|
|
JP2007523171A |
Lysergic acid is formed in high yields and high quality by isomerizing paspalic acid in a phase separated mixture formed by paspalic acid and a concentrated aqueous metal hydroxide solution.
|
|
JP2007501274A |
Provided are new crystalline Forms VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.
|
|
JP2006265183A |
To provide a method for producing a pergolide preparation exhibiting sufficient stability without using cold form wrapping which is expensive and cannot be visually checked the inside.The method for producing pergolide tablet comprises c...
|
|
JP3725153B2 |
Compsn. contains ergoline derivs. opt. in combination with one or more penetration promoters. The ergoline deriv. is of formula (I); where the dotted line represents an opt. bond; R1 = H, halo or 1-4C alkylthio; R2 = 1-4C alkyl; salt of ...
|
|
JP2005529856A |
A process for producing crystalline form I of cabergoline, which process comprises the preparation of Form V using heptane as precipitation solvent, and its exclusive conversion into crystalline Form I of cabergoline. The present crystal...
|
|
JP2005529084A |
Parecoxib sodium is provided in a crystalline form that is substantially anhydrous and substantially nonsolvated. Various such anhydrous, nonsolvated crystal forms have been identified, including Forms A, B and E as described herein. Als...
|
|
JP2005520833A |
A process for the synthesis of pergolide (Formula (I)) (D-6-n-propyl-8betamethylmercaptomethylergo line) from acid 9,10-dihydrolysergic is herein disclosed. The process can be carried out without isolating most intermediates and is parti...
|
|
JP2005520831A |
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of th...
|
|
JP3580565B2 |
PURPOSE: To produce pergolide by a one-pot reaction by allowing 8,9- dihydroelymoclavine to react successively with 1-iodopropane, with a sulfonyl halide and with an alkali metallic thiomethoxide. CONSTITUTION: A compd. of formula I is a...
|
|
JP2004530631A |
Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingred...
|
|
JP2004525187A |
A process for preparation of N-(ergoline-8 beta -carbonyl)ureas of the formula [I] their stereoisomers as well as acid addition salts thereof which process comprises silylating an ergoline -8 beta -carboxamide of the formula [2], their s...
|
|
JP2004512305A |
The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and anoth...
|
|
JP2004506682A |
Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingred...
|
|
JP2004505917A |
A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.
|
|
JP2003528873A |
Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture of forms I and VII of cabergoline in a s...
|
|
JP2003528874A |
Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temp...
|
|
JP2002536441A |
The invention provides a compound of formula I wherein R, X, Y1 and Y2 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.
|
|
JP3339858B2 |
The invention provides a process for the preparation of ergoline derivatives of the formula I I the process comprising reacting an ergoline amide of the formula II with an isocyanate of formula III in presence of a metal catalyst and of ...
|
|
JP3337688B2 |
The present invention provides compounds of the formula (I) wherein A, R1, R2 and R3 are defined as in the specification, or a pharmaceutically acceptable salt thereof. A process for their preparation and the pharmacetical compositions c...
|
|
JP2002520411A |
The invention relates to novel derivatives of ergoline of the general formula 1in which R1 together with the two adjacent N atoms is the residue of a diamine and R4 together with the two adjacent carbonyl groups is the residue of a dicar...
|
|
JP2002003500A |
To obtain a new lysergic acid diethylamide(LSD) and an iso-LSD, a new hapten and a new immunogen of an oxidized LSD and an antibody derived from the immunogen and to provide a method for immunoassay utilizing the antibody.This hapten der...
|
|
JP2001527580A |
The invention provides compounds of formula Iwherein R1 to R6 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.
|
|
JP2000513365A |
PCT No. PCT/EP97/02955 Sec. 371 Date Dec. 28, 1998 Sec. 102(e) Date Dec. 28, 1998 PCT Filed May 29, 1987 PCT Pub. No. WO98/00424 PCT Pub. Date Jan. 8, 1998The present invention provides the new use in the treatment of neurodegenerative d...
|
|
JP2000504700A |
PCT No. PCT/EP97/00582 Sec. 371 Date Aug. 17, 1998 Sec. 102(e) Date Aug. 17, 1998 PCT Filed Feb. 7, 1997 PCT Pub. No. WO97/30050 PCT Pub. Date Aug. 21, 1997Ergoline derivative having formula (I) wherein R1 is hydrogen atom or C1-4 alkyl ...
|
